Roth Capital Initiates Galmed Pharmaceuticals At Buy

Roth Capital initiated coverage on Galmed Pharmaceuticals Ltd GLMD with a Buy rating. The target price for Galmed Pharmaceuticals is set to $20. Galmed Pharmaceuticals shares have dropped 1.24% over the past 52 weeks, while the S&P 500 index has surged 12.54% in the same period. Galmed Pharmaceuticals' shares fell 3.94% to close at $8.78 yesterday.